Comment
Author: Admin | 2025-04-28
Florham Park, NJ: Shionogi & Co.; 2019.LORBRENA [package insert]. New York, NY: Pfizer Labs; 2018.U.S. Food & Drug Administration. Drugs@FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000TOC.cfm. Accessed January 26, 2020.RYDAPT [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.U.S. Food & Drug Administration. Drugs@FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000TOC.cfm. Accessed January 20, 2020.NERLYNX [package insert]. Los Angeles, CA: Puma Biotechnology, Inc.; 2018.U.S. Food & Drug Administration. Drugs@FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208051Orig1s000TOC.cfm. Accessed January 26, 2020.ZEJULA [package insert]. Waltham, MA: TESARO, Inc.; 2019.TURALIO [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2019.U.S. Food & Drug Administration. Drugs@FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000TOC.cfm. Accessed January 26, 2020.RUBRACA [package insert]. Boulder, CO: Clovis Oncology, Inc.; 2018.XPOVIO [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; 2019.TALZENNA [package insert]. New York, NY: Pfizer Labs; 2019.U.S. Food & Drug Administration. Drugs@FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000TOC.cfm. Accessed January 21, 2020.Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol. 2018;74(4):413–21.Article CAS Google Scholar Porta-Sanchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, diagnosis and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017;6:e007724.Article Google Scholar Strevel E, Ing D, Siu L. Moleculary targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol. 2007;25:3362–71.Article CAS Google Scholar Woolsey RL, Heise CW, Gallo T, et al: QTdrugs list. https://crediblemeds.org/ Accessed October 7, 2019.•• Rogala B, Charpentier M, Nguyen M, Landolf K, Hamad L, Gaertner K. Oral anticancer therapy: management of drug interactions. J Oncol Pract. 2019;15:81–90 Recent high quality review of all oral chemotherapy and management of drug-drug interactions.Article Google Scholar Maschmeyer G, DeGreef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33:844–62.Article CAS Google Scholar Reinwald M, Silva JT, Mueller NJ, Fortun J, Garzoni C, de Fijter JW, et al. ESCMID study group for infections in compromised hosts (ESGICH) Consenus Document on the safety of targeted and biological therapies: an infectious diseases perspective
Add Comment